References
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
- Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317.
- Berdeja JG, Savona MR, Chu L, et al. Bendamustine, bortezomib, and dexamethasone (BBD) as first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Blood (Suppl). 2013;122:3193.
- Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3:e162
- Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985–991.
- Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473 (Errata in: Leukemia 2006;20(12):2220, and Leukemia 2007;21(5):1134).
- Rich JT, Neely JG, Paniello RC, et al. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143:331–336.
- Rodon P, Hulin C, Pegourie B, et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica 2015;100:e56–e59.
- Pönisch W, Holzvogt B, Plötze M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014;140:1947–1956.
- Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172.
- Zhang S, Wang X, Chen L, et al. Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cells. Blood (Suppl) 2008;112:Abstract 5171.
- Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90:314–319.
- Hsieh PY, Liu CJ, Teng CJ. Immortal time bias and reverse causality in retrospective analysis: comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study”. Am J Hematol. 2015;90:E146.
- Surget S, Lemieux-Blanchard E, Maïga S, et al. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma. 2014;55:2165–2173.
- Cives M, Ciavarella S, Rizzo FM, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013;25:1108–1117.
- Mateos MV, Oriol A, Rosiñol L, et al. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. Haematologica. 2015;100:1096–1102.
- Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28:258–268.